Back to results
US 2025/0082587 A1Published application
Method Of Treating Major Depressive Disorder
AssigneeClexio Biosciences Ltd.
InventorDavid DANGOOR
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods for safe and efficacious administration of esketamine and pharmaceutically acceptable salts thereof.
Claims20
A method of treating major depressive disorder (MDD) in a subject in need thereof comprising:
- a) determining or having determined said subject's Montgomery-Åsberg Depression Rating Scale (MADRS) score, and
- b) orally administering an immediate release oral dosage form comprising 60 mg of esketamine or a pharmaceutically acceptable salt thereof, once daily for at least 28 days to the subject that is determined to have a Montgomery-Åsberg Depression Rating Scale (MADRS) score of at least 28.
A method of treating major depressive disorder (MDD) in a subject in need thereof comprising:
- a) determining or having determined whether said subject's Montgomery-Åsberg Depression Rating Scale (MADRS) score is at least 28, and
- b) orally administering an immediate release oral dosage form comprising 60 mg of immediate release esketamine or a pharmaceutically acceptable salt thereof, once daily for at least 28 days to the subject that is determined to have a Montgomery-Åsberg Depression Rating Scale (MADRS) score of at least 28.
A method of treating major depressive disorder (MDD) in a subject in need thereof comprising:
- a) determining or having determined that said subject's Montgomery-Åsberg Depression Rating Scale (MADRS) score is at least 28, and
- b) orally administering an immediate release oral dosage form comprising 60 mg of immediate release esketamine or a pharmaceutically acceptable salt thereof, once daily for at least 28 days to the subject that is determined to have a Montgomery-Åsberg Depression Rating Scale (MADRS) score of at least 28.
A method of treating major depressive disorder (MDD) in a subject in need thereof comprising:
- a) determining or having determined said subject's Montgomery-Åsberg Depression Rating Scale (MADRS) score, and
- b) orally administering an immediate release oral dosage form comprising 60 mg of esketamine or a pharmaceutically acceptable salt thereof, to the subject that is determined to have a Montgomery-Åsberg Depression Rating Scale (MADRS) score of at least 28;
- and
- wherein the administration is once daily for at least 28 days.
1 more element
Dependencies are inferred from the claim text.